Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Myxoid leiomyosarcoma: A population-based NCDB analysis.

Karissa Gonzalez, Trishla Mehta, Tyson Morris et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17611

e17611 Background: Myxoid leiomyosarcoma is a rare malignant smooth muscle tumor characterized by abundant myxoid stroma a...

ICONIC (Improving Outcomes Through Collaboration in Osteosarcoma): Insights from a national prospective cohort trial for newly diagnosed osteosarcoma patients.

Sandra J. Strauss, Bernadette Brennan, Nischalan Pillay et al. Jun 01, 2026 pp. 11524-11524 10.1200/jco.2026.44.16_suppl.11524

11524 Background: There has been little change in osteosarcoma (OS) treatment over the last two decades. Understanding man...

Efficacy and safety of telpegfilgrastim in the prophylaxis of chemotherapy-induced neutropenia in breast cancer patients: A retrospective study.

Yanxia Shi Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12515

e12515 Background: Chemotherapy-induced neutropenia (CIN) is a common complication during cancer chemotherapy, leading to...

An alternative approach to limiting surgical and radiation stress in patients with glioblastoma.

Eduard E. Rostorguev, Alla Ivanovna Shikhlyarova, Elena M. Frantsiyants et al. Jun 01, 2026 pp. 2062-2062 10.1200/jco.2026.44.16_suppl.2062

2062 Background: While neuro-oncology has seen global advances in high-tech diagnostics and treatments for brain tumors, t...

Guard-01: A randomized, open-label trial of efbemalenograstim alfa as primary prophylaxis for neutropenia during definitive concurrent chemo-radiotherapy.

Yuanyuan Chen, Qiwen Li, Zunbei Wen et al. Jun 01, 2026 pp. 12060-12060 10.1200/jco.2026.44.16_suppl.12060

12060 Background: Concurrent chemoradiotherapy (CCRT), a curative cornerstone for locally advanced malignancies, exerts sy...

USP10 activity as sensitizer of lung adenocarcinoma to immune checkpoint inhibitors: Upregulating PD-L1 via the ANT3-mediated activation of the cGAS-STING pathway.

Aman Wang, Mengyuan Xu, Zhen Ning et al. Jun 01, 2026 pp. 8542-8542 10.1200/jco.2026.44.16_suppl.8542

8542 Background: Although immune checkpoint inhibitors (ICIs) have reshaped the treatment landscape for advanced lung aden...

Empowering multidisciplinary teams in cancer survivorship: Results from the ASCO Project ECHO survivorship program in Brazil.

Luciana Castro Landeiro, Thaiana Aragão Santana, Clarissa Mathias et al. Jun 01, 2026 pp. 11096-11096 10.1200/jco.2026.44.16_suppl.11096

11096 Background: As the number of cancer survivors increases in Brazil, access to structured survivorship education for h...

Treatment outcomes with pembrolizumab and chemotherapy in metastatic metaplastic triple-negative breast cancer: Data from a central European cohort.

Justyna Żubrowska, Malgorzata Podskarbi, Aleksandra Konieczna et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13119

e13119 Background: Metaplastic triple-negative breast cancer (MpTNBC) is a rare and clinically aggressive subtype of breas...

Efficacy and safety of cadonilimab (CD) in combination with disitamab vedotin (RC48) or nab-paclitaxel (NP) in the treatment of recurrent or metastatic cervical cancer (r/mCC): A prospective, double-cohort, multicenter, open-label, phase II clinical study.

Min Zheng, Haifeng Gu, Jian Zhou et al. Jun 01, 2026 pp. 5526-5526 10.1200/jco.2026.44.16_suppl.5526

5526 Background: The prognosis for patients(pts) with r/mCC is poor. The available second-line treatment regimens are limi...

Final results of the phase III OCTAVA trial: Clinical benefit of low-dose anti–CTLA-4 plus anti–PD-1 combination vs anti–PD-1 monotherapy in unresectable or metastatic melanoma.

Lev V. Demidov, Igor V. Samoylenko, Galina Kharkevich et al. Jun 01, 2026 pp. 9544-9544 10.1200/jco.2026.44.16_suppl.9544

9544 Background: BCD-217-2/OCTAVA is an international, multi-center, randomized, double-blind, placebo-controlled phase II...

An intervention in disguise: An immersive care model for families where a parent has a brain tumor.

Abigail Marks, Elizabeth Bobrovnikov, Lily C. Gebhart et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13551

e13551 Background: Having a parent with brain cancer deeply impacts the family unit, leading to increased isolation and lo...

Real-world experience of a pediatric precision oncology protocol utilizing paired somatic and germline sequencing at a single institution: Interim analysis.

Joshua Goldman, Malay Mody, Lucas Ebert et al. Jun 01, 2026 pp. 10008-10008 10.1200/jco.2026.44.16_suppl.10008

10008 Background: While most pediatric oncology patients are cured with upfront therapy, outcomes for patients with metast...

Landscape of the immune microenvironment in malignant pleural effusion from EGFR-TKI-resistant NSCLC.

Yangchun Gu, Abudureyimujiang Aili, Zhentao Liu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20532

e20532 Background: Malignant pleural effusion (MPE) is a poor prognostic factor in non-small cell lung cancer (NSCLC), whi...

Platinum-based chemotherapy in early-stage, high-risk, triple-negative breast cancer: A systematic review and meta-analysis of randomized trials.

Jessé Lopes da Silva, Mariana Carvalho Gouveia, Anelise Poluboiarinov Cappellaro et al. Jun 01, 2026 pp. 529-529 10.1200/jco.2026.44.16_suppl.529

529 Background: The clinical benefit of adding platinum agents to adjuvant chemotherapy for early-stage triple-negative br...

Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML).

WeiMing Li, Yanli Zhang, Huanling Zhu et al. Jun 01, 2026 pp. 6510-6510 10.1200/jco.2026.44.16_suppl.6510

6510 Background: Olverembatinib is a third-generation BCR::ABL1 tyrosine kinase inhibitor (TKI) approved in China for chro...

Effect of neoadjuvant radiotherapy combined with surgery on long-term prognosis of patients with centrally located hepatocellular carcinoma: A machine learning and propensity score weighting analysis.

Changcheng Tao, Jianxiong Wu, Nan Hu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16259

e16259 Background: Primary liver cancer is the sixth most common malignancy globally and the third leading cause of cancer...

When disaster strikes: A scoping review of climate-resilience toolkits relevant to cancer care delivery.

Kamryn Thomas, Konrad Malik, Caroline Walsh et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23198

e23198 Background: External disruptions, such as extreme weather and infrastructure failures,are increasingly undermining...

Early versus delayed biologic therapy for immune checkpoint inhibitor–associated colitis: A propensity-matched real-world analysis.

Jamil Nazzal, Mohammad Salameh, Zaid Zahid et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24204

e24204 Background: Immune checkpoint inhibitor (ICI)–associated colitis is a clinically significant immune-related adverse...

Sequential use of antibody-drug conjugates in advanced breast cancer: A real-world study based on HER2 status.

Gang Li, Qing Qu, W Zhu et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13020

e13020 Background: The optimal sequencing strategy for antibody-drug conjugates (ADCs) following progression on prior ADC...

Cardiac safety of L-annamycin at high cumulative anthracycline exposure: Pooled analysis.

Robert C. Shepard, Erikson Wasyl, Patrick Collier et al. Jun 01, 2026 pp. 12025-12025 10.1200/jco.2026.44.16_suppl.12025

12025 Background: Anthracyclines are widely used chemotherapeutic agents but limited by dose-dependent cardiotoxicity and...

The complementary anti-cancer and analgesic properties of the natural product barettin.

Caleb Seekins, Julia Podgorski, Nam Lee et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15129

e15129 Background: Chemotherapy induced peripheral neuropathy (CIPN) is one of the most common side effects of chemotherap...

Alcohol and cancer risk: A review of messaging content on websites of medical, cancer, government, and nonprofit organizations and alcohol companies.

Zhu Chin Ng, Sharouk Khanjar, Michael Siegel Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22508

e22508 Background: Alcohol is a risk factor for multiple cancers, yet there is limited awareness of this risk relationship...

Trends in U.S. pneumonia-related admissions among patients with multiple myeloma (2006–2022).

Jackson R. Brunner, Kristian Seiler, Matthew J. Pianko Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19535

e19535 Background: Despite improvements in survival due to novel therapies, patients with multiple myeloma (MM) experience...

Clinical profile, treatment patterns, and survival outcomes of multiple myeloma patients in the Middle East: Real-world data from Bahrain.

Shruti Prem Sudha, Amal Almutawa, Nabil Abdelfattah et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19576

e19576 Background: Real-world data from the Middle East in myeloma is limited, despite unique demographic factors that may...

Influence of genetic ancestry on UV mutational signatures linked to immunotherapy response in melanoma, beyond TMB.

Kevin Magnaye, Brady Gilg, Lauren R. Dickman et al. Jun 01, 2026 pp. 3087-3087 10.1200/jco.2026.44.16_suppl.3087

3087 Background: Melanoma is a UV-driven malignancy with substantial biological heterogeneity, yet genomic profiling effor...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page